Loading
AINOSTICS
AINOSTICS develops AI and MRI-measurement software for the early diagnosis and management of neurological conditions such as Alzheimer's, Huntington's and MS. Its products include BR[AI]N, which predicts conversion to Alzheimer's from structural MRI, and the IQ multimodal inference and quantification engine. It sells to pharmaceutical companies running therapeutic trials and to clinicians, through a remote-access platform. The company says it secured about $2.5M in 2020 and won the Med-Tech Innovation Award (Connected Health) in 2021.
Funding
Every round, secondary, debt facility or acquisition involving AINOSTICS that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
—